Effector Function in Biologics: Why ADCC, CDC and Cell-Based Potency Assays Define True Therapeutic Performance

“Effector function in monoclonal antibodies refers to immune-response activation mediated primarily by the Fc region, such as antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.”

For modern biologics, binding affinity alone no longer defines therapeutic performance. Especially in monoclonal antibodies, bispecifics, and other advanced modalities, the decisive factor lies in what happens after target engagement: the activation of immune effector functions.

“Effector function in monoclonal antibodies refers to immune-response activation mediated primarily by the Fc region, such as antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity,” explains Dr. Christian Klein, Laboratory Manager Cell-based Assays at ProtaGene. “These mechanisms can enhance therapeutic efficacy but may also represent unintended effects that need to be carefully controlled.”

Effector functions such as ADCC and CDC are often integral to a molecule’s mode of action. They drive target cell elimination and directly influence clinical outcomes. At the same time, they are critical from a safety and regulatory perspective, as their variability can impact both efficacy and risk profiles. This makes their reliable characterization a central requirement throughout development.

Yet, this is precisely where conventional analytical approaches reach their limits. Cell-based assays, which are essential for measuring effector function, inherently depend on living systems. Variability in effector and target cells, sensitivity to assay conditions, and fluctuations in critical reagents can significantly affect assay performance and reproducibility.

“Cell-based ADCC and CDC assays face challenges such as limited reproducibility and high sensitivity to assay conditions,” says Dr. Klein. “To address this, standardized or engineered effector cells, reporter-based readouts, and carefully controlled assay conditions are essential to ensure comparability and reliability.”

A key challenge lies in controlling biological variability, particularly when critical reagents such as human complement serum are involved. Differences between serum lots can directly influence assay outcomes and mask or exaggerate functional effects. Robust strategies therefore require not only the use of pooled serum to average donor variability, but also systematic side-by-side comparisons of new and existing lots across the assay’s range.

“Changes in assay conditions can shift the position, steepness, and variability of the dose-response curve.”

Beyond reagent control, assay design itself plays a decisive role. Parameters such as cell number, starting concentration, dilution schemes, and incubation times directly shape the dose-response curve. Only a carefully optimized, sigmoidal response allows for the reliable differentiation of potency changes.

“Changes in assay conditions can shift the position, steepness, and variability of the dose-response curve,” Dr. Klein emphasizes. “Optimizing these parameters is essential to generate robust and interpretable results.”

Importantly, functional characterization cannot be separated from structural analysis. Modifications at the molecular level can directly translate into altered biological activity. Oxidation near critical regions, for example, can reduce binding and ultimately impact potency in both binding and cell-based assays.

“Structural modifications can be directly linked to potency changes when their analytical detection aligns with functional readouts,” Dr. Klein explains. “This connection is essential for understanding the true impact of molecular changes.”

Given this complexity, the development of cell-based potency assays must start early in the lifecycle of a biologic. These assays serve as the primary measure of biological activity and must be capable of detecting changes arising from process development, manufacturing variability, and product degradation.

“Early assay development is crucial to ensure that robustness is built in from the beginning and that assays are ready to support clinical development and comparability assessments,” says Dr. Klein.

At ProtaGene, this challenge is addressed through a structured, quality-driven approach to assay development and qualification. Robustness is treated as a cornerstone, with systematic variation of critical parameters and evaluation of assay performance across defined potency ranges. Qualification strategies are aligned with ICH guidelines, covering key parameters such as repeatability, specificity, intermediate precision, accuracy, linearity, and range.

“What truly matters is whether we can reliably translate these insights into functional understanding.”

In addition, reporter gene assays are increasingly used as a complementary or alternative approach. While maintaining comparable activity trends to classical assays, they offer advantages in sensitivity, reproducibility, and reduced donor-to-donor variability, making them particularly suitable for routine potency testing.

Taken together, these strategies enable a deeper and more reliable understanding of effector function. They allow developers not only to confirm that a biologic binds to its target, but to demonstrate that it performs as intended within the immune system.

“In the end, it is not enough to understand a molecule analytically,” Dr. Klein concludes. “What truly matters is whether we can reliably translate these insights into functional understanding. Only then can we ensure that biologics consistently deliver the performance they are designed for.”

As biologics continue to grow in complexity, this shift towards functional understanding is becoming increasingly critical. The ability to robustly characterize effector function is no longer a downstream task. It is a central element of development, comparability, quality and ultimately a prerequisite for ensuring that therapeutic intent translates into clinical reality.

About Dr. Christian Klein:

Dr. Christian Klein holds a Ph.D. in Chemical Biology from the TU Dortmund, focusing on cell-based assays already during his doctoral studies. Before joining ProtaGene he worked several years as Senior Scientist in a leading biosimilar company. At ProtaGene, he built up a cell culture and cell-based assay lab from scratch, all qualified/validated for GMP. Together with his team of experienced (and highly motivated) scientists he is driving the development and qualification of cell-based assays for a variety of customers.

In his free time, he enjoys spending time with his son as well as ballroom dancing and traveling.

Upcoming Webinar with Dr. Christian Klein:

“Beyond Cytotoxicity A Deep Dive into Effector Function with Advanced Cell Based Platforms”
Dr. Christian Klein
April 29, 4:00 – 4:45 PM CEST

Register for our Upcoming Webinar